What type of drug does Alpelisib belong to?

Alpelisib(Alpelisib)-Piqray is an oral targeted anti-cancer drug that is a PI3Kα (phosphatidylinositol 3-kinase α) inhibitor. The PI3K signaling pathway is abnormally activated in a variety of tumors, especially in breast cancer, ovarian cancer and some gastrointestinal tumors. PIK3CA gene mutations can lead to increased tumor growth, proliferation and drug resistance. By selectively inhibiting PI3Kα isoforms, Apelvis blocks downstream signal transduction, thereby slowing down tumor cell proliferation and inducing apoptosis, and may also improve the efficacy of endocrine therapy-resistant breast cancer patients.

In clinical application, apelvis is often used in combination with endocrine therapy drugs (such as fulvestrant) to treat HR-positive, HER2-negative advanced breast cancer with PIK3CA mutations. Its emergence fills the gap in targeted therapy for PIK3CA mutated tumors and provides personalized treatment options for patients with gene-driven breast cancer. Compared with traditional chemotherapy drugs, the selective targeting effect of Apelvis makes its side effect spectrum relatively controllable. Common adverse reactions include increased blood sugar, rash and gastrointestinal symptoms.

The development and launch of Apelvis marks the development direction of precision tumor treatment, that is, identifying patient-specific mutations through genetic testing and selecting targeted drugs for treatment. This precision treatment strategy can not only improve the efficacy, but also potentially reduce the toxic effects on normal tissues. It is an increasingly important treatment concept in modern oncology. At the same time, the pharmacological mechanism and safety of Apelvis have made it an important subject for research on the treatment of various gene-driven tumors. Relevant clinical studies are being carried out in many countries and regions around the world to explore its application potential in different cancer types and treatment combinations.

In general, Apelvis is an oral targeted drug targeting specific gene mutations. It delays tumor progression by precisely inhibiting the PI3Kα signaling pathway, providing personalized treatment options for breast cancer patients. It also provides reference and practical experience for future treatment of gene-driven tumors.

Reference materials:https://www.piqray.com/